Funding Opportunities

• Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R41/R42 Clinical Trial Not Allowed)
  (PA-19-033)
  National Institute of Dental and Craniofacial Research
  National Cancer Institute
  National Heart, Lung, and Blood Institute
  National Library of Medicine
  National Institute of Mental Health
  National Center for Advancing Translational Sciences
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): Standard dates apply by 5:00 PM local time of applicant organization. *** Note new SBIR/STTR Standard Due Dates.
• Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R43/R44 Clinical Trial Not Allowed)
  (PA-19-034)
  National Institute of Dental and Craniofacial Research
  National Cancer Institute
  National Heart, Lung, and Blood Institute
  National Library of Medicine
  National Institute of Mental Health
  National Center for Advancing Translational Sciences
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): Standard dates apply by 5:00 PM local time of applicant organization. *** Note new SBIR/STTR Standard Due Dates.
• Administrative Supplements to Cancer Center Support Grants to Strengthen NCI-Supported Community Outreach Capacity through Community Health Educators of the National Outreach Network (Admin Suppl Clinical Trial Not Allowed)
  (PA-19-035)
  National Cancer Institute
  Application Receipt Date(s): December 15, 2018, by 10:00 AM EDT. Late applications will not be accepted. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• NLM Grants for Scholarly Works in Biomedicine and Health (G13 Clinical Trial Not Allowed)
  (PAR-19-032)
  National Library of Medicine
  Application Receipt Date(s): February 26, 2019 and February 26, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• Medical Scientist Training Program (T32)
  (PAR-19-036)
  National Institute of General Medical Sciences
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first application due date for this FOA is May 25, 2019. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Initiative for Maximizing Student Development (IMSD) (T32)
  (PAR-19-037)
  National Institute of General Medical Sciences
  Application Receipt Date(s): February 22, 2019; January 28, 2020; January 28, 2021, by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Emerging Global Leader Award (K43 Independent Clinical Trial Required)
  (PAR-19-038)
  John E. Fogarty International Center
  National Cancer Institute
  National Institute of Dental and Craniofacial Research
  National Institute of Environmental Health Sciences
  National Human Genome Research Institute
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  Office of Research on Women's Health
  Application Receipt Date(s): November 28, 2018; November 7, 2019; and November 4, 2020 by 5:00 PM local time of the applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01 Clinical Trial Not Allowed)
  (PAR-19-039)
  National Institute of Neurological Disorders and Stroke
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  National Eye Institute
  Application Receipt Date(s): September 10, 2019; October 8, 2020; September 14, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional)
  (PAR-19-040)
  National Institute of Neurological Disorders and Stroke
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  National Eye Institute
  Application Receipt Date(s): September 10, 2019; October 8, 2020, September 14, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Development of Personalized In Vitro Assays to Quantitatively Assess Age-related Changes in Cellular Resiliencies to Physiologic Stressors (R43/R44 Clinical Trial Not Allowed)
  (RFA-AG-19-025)
  National Institute on Aging
  Application Receipt Date(s): March 8, 2019, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Development of Personalized In Vitro Assays to Quantitatively Assess Age-related Changes in Cellular Resiliencies to Physiologic Stressors (R41/R42 Clinical Trial Not Allowed)
  (RFA-AG-19-026)
  National Institute on Aging
  Application Receipt Date(s): March 8, 2019, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• A Census of Cells and Circuits in the Aging Brain (R01 Clinical Trial Not Allowed)
  (RFA-AG-19-027)
  National Institute on Aging
  Application Receipt Date(s): March 8, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01)
  (RFA-FD-20-001)
  Food and Drug Administration
  Application Receipt Date(s): June 25, 2019, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
• Reproductive Medicine Collaborative Clinical Trials Program (Collaborative R01 Clinical Trial Required)
  (RFA-HD-19-022)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): January 18, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Early Screening for Autism Spectrum Disorder (R01 Clinical Trial Not Allowed)
  (RFA-MH-19-120)
  National Institute of Mental Health
  National Institute on Deafness and Other Communication Disorders
  National Institute of Environmental Health Sciences
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): February 4, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement.
• Early Screening for Autism Spectrum Disorder (R21 Clinical Trial Not Allowed)
  (RFA-MH-19-121)
  National Institute of Mental Health
  National Institute on Deafness and Other Communication Disorders
  National Institute of Environmental Health Sciences
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): February 4, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement?.
• NINDS Morris K. Udall Centers of Excellence for Parkinsons Disease Research (P50 Clinical Trial Optional)
  (RFA-NS-18-026)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): January 11, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• NINDS Morris K. Udall Center without Walls for Parkinsons Disease Research (P20 Clinical Trial Optional)
  (RFA-NS-18-027)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): January 11, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• BRAIN Initiative: Research Resource Grants for Technology Integration and Dissemination (U24 Clinical Trial Not Allowed)
  (RFA-NS-19-006)
  National Institute of Neurological Disorders and Stroke
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Aging
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Eye Institute
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Institute of Biomedical Imaging and Bioengineering
  Application Receipt Date(s): January 4, 2019, June 27 2019, February 27, 2020, November 27, 2020, June 27, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.